

ICMJE DISCLOSURE FORM

Date: 03/08//2026
Your Name: Yanina M. M. Castaño

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.


	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1"> <tr><td>None</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table> Click the tab key to add additional rows.	None					
None								
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1"> <tr><td>None</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	None					
None								
3	Royalties or licenses	☒ None <table border="1"> <tr><td>None</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	None					
None								

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None Laboratorio Eurofarma Laboratorio Boehringer Ingelheim Laboratorio Astra Zeneca	
6	Payment for expert testimony	☒ None None	
7	Support for attending meetings and/or travel	☒ None Laboratorio Elea Medtronic Laboratorio Novo Nordisk Laboratorio Adium	
8	Patents planned, issued or pending	☒ None None	
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None None	
ju m pj u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None 	
13	Other financial or non-financial interests	☒ None None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

 04/08/26

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: Martín A. Maraschio

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>						
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>						
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>						

4	Consulting fees	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>								
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>								
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>								
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>								
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>								
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>								
ju m pj u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>								
11	Stock or stock									

212/13/2021ICMJE Disclosure Form

	options	☒ None						
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
13	Other financial or non-financial interests	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.								



Dr. MARTIN A. MARASCHIO
 ESP. JERARQUIZADO EN
 CLINICA MEDICA
 C/A DIABETOLOGIA
 M.P. 81835

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: Fabiana P. Vázquez

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table> Click the tab key to add additional rows.						
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
3	Royalties or licenses	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	None <table border="1"> <tr> <td>Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, NovoNordisk, Novartis, Sanofi.</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, NovoNordisk, Novartis, Sanofi.							
Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, NovoNordisk, Novartis, Sanofi.											
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None <table border="1"> <tr> <td>Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, NovoNordisk, Novartis, Sanofi</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, NovoNordisk, Novartis, Sanofi							
Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, NovoNordisk, Novartis, Sanofi											
6	Payment for expert testimony	None <table border="1"> <tr> <td>Adium, Boehringer-Ingelheim, Elea.</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		Adium, Boehringer-Ingelheim, Elea.							
Adium, Boehringer-Ingelheim, Elea.											
7	Support for attending meetings and/or travel	None <table border="1"> <tr> <td>Adium, Elea, Gador, Sanofi,</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		Adium, Elea, Gador, Sanofi,							
Adium, Elea, Gador, Sanofi,											
8	Patents planned, issued or pending	☒ None <table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	None <table border="1"> <tr> <td>Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, Sanofi</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, Sanofi							
Adium, Boehringer-Ingelheim, Elea, Glaxo, Nolter, Sanofi											
ju m pj u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None <table border="1"> <tr> <td>Sociedad Argentina de Diabetes</td> <td></td> </tr> <tr> <td>Sociedad Argentina de Nutrición</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		Sociedad Argentina de Diabetes		Sociedad Argentina de Nutrición					
Sociedad Argentina de Diabetes											
Sociedad Argentina de Nutrición											

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None 	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None 	
13	Other financial or non-financial interests	☒ None 	
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			


 Fabiana Vázquez
 Médica esp. Nutrición.
 Diabetes
 MN 86573 MP 444167

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: Diego Sebastian Novielli

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
ju m pj u m	Leadership or fiduciary role in other board, society, committee or	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
p1 0	advocacy group, paid or unpaid								
11	Stock or stock options	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.									



Dr. DIEGO NOVELLI
CARDIOLOGO
M.P. 233699 M.N. 101215

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: Gustavo M.M. Lavenia

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1"> <tr> <td>NONE</td> <td>NONE</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td>Click the tab key to add additional rows.</td> </tr> </table>		NONE	NONE				Click the tab key to add additional rows.
NONE	NONE								
	Click the tab key to add additional rows.								
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1"> <tr> <td>NONE</td> <td>NONE</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		NONE	NONE				
NONE	NONE								
3	Royalties or licenses	☒ None <table border="1"> <tr> <td>NONE</td> <td>NONE</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		NONE	NONE				
NONE	NONE								

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<table border="1"> <tr> <td>NOVO NORDISK</td> <td>NONE</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		NOVO NORDISK	NONE						
NOVO NORDISK	NONE										
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<table border="1"> <tr> <td>NOVO NORDISK</td> <td>NONE</td> </tr> <tr> <td>BOEHRINGER INGELHEIM</td> <td>NONE</td> </tr> <tr> <td>BAYER</td> <td>NONE</td> </tr> </table>		NOVO NORDISK	NONE	BOEHRINGER INGELHEIM	NONE	BAYER	NONE		
NOVO NORDISK	NONE										
BOEHRINGER INGELHEIM	NONE										
BAYER	NONE										
6	Payment for expert testimony	☒ None <table border="1"> <tr> <td>NONE</td> <td>NONE</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		NONE	NONE						
NONE	NONE										
7	Support for attending meetings and/or travel	<table border="1"> <tr> <td>BOEHRINGER INGELHEIM</td> <td></td> </tr> <tr> <td>BALIARDA</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		BOEHRINGER INGELHEIM		BALIARDA					
BOEHRINGER INGELHEIM											
BALIARDA											
8	Patents planned, issued or pending	☒ None <table border="1"> <tr> <td>NONE</td> <td>NONE</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		NONE	NONE						
NONE	NONE										
	Participation on a Data Safety Monitoring Board or Advisory Board	<table border="1"> <tr> <td>NOVO NORDISK</td> <td>NONE</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		NOVO NORDISK	NONE						
NOVO NORDISK	NONE										
ju m p j u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr> <td>NONE</td> <td>NONE</td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>		NONE	NONE						
NONE	NONE										

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None	
		NONE	NONE
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
		NONE	NONE
13	Other financial or non-financial interests	☒ None	
		NONE	NONE

Please place an "X" next to the following statement to indicate your agreement:

☒ X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Dr. GUSTAVO LAVENIA
M.P. 12495
NEFROLOGÍA 30/062
MAGISTER EN HIPERTENSIÓN
Y MECÁNICA VASCULAR

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: Ezequiel H. Forte

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None <table border="1" data-bbox="386 302 1520 441"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ YES <table border="1" data-bbox="386 579 1520 718"> <tr> <td>Honoaria for lectures: Novo Nordisk, Boheringer, Adium, Elea, Casasco</td> <td></td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Honoaria for lectures: Novo Nordisk, Boheringer, Adium, Elea, Casasco							
Honoaria for lectures: Novo Nordisk, Boheringer, Adium, Elea, Casasco											
6	Payment for expert testimony	☒ None <table border="1" data-bbox="386 903 1520 1012"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☒ YES <table border="1" data-bbox="386 1150 1520 1255"> <tr> <td>Elea, Adium, Casasco, NovoNordisk</td> <td></td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		Elea, Adium, Casasco, NovoNordisk							
Elea, Adium, Casasco, NovoNordisk											
8	Patents planned, issued or pending	☒ None <table border="1" data-bbox="386 1394 1520 1499"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1" data-bbox="386 1638 1520 1743"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
ju m pj u m	Leadership or fiduciary role in other board, society, committee or	☒ YES <table border="1" data-bbox="386 1881 1520 1944"> <tr> <td>Secretary of Interamerican Society of Cardiology</td> <td></td> </tr> <tr><td></td><td></td></tr> </table>		Secretary of Interamerican Society of Cardiology							
Secretary of Interamerican Society of Cardiology											

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
p1 0	advocacy group, paid or unpaid		
11	Stock or stock options	☒ None 	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None 	
13	Other financial or non-financial interests	☒ None 	
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			



Dr Ezequiel Forte
DNI 24114463

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: Alicia Elbert

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 2px;">none</td> <td style="width: 50%;"></td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> </table> Click the tab key to add additional rows.		none					
none									
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 2px;">Miembro del Board de Speakers de AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi , Servier, Raffo , Baliarda.</td> <td style="width: 50%;"></td> </tr> <tr> <td style="padding: 2px;">Investigadora en Estudio de Novonordisk , Abbie, Bayer, Biosidus, Glaxo, Boehringer Ingelheim, Astra Zeneca, Merck.</td> <td></td> </tr> <tr> <td style="height: 20px;"></td> <td></td> </tr> </table>		Miembro del Board de Speakers de AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi , Servier, Raffo , Baliarda.		Investigadora en Estudio de Novonordisk , Abbie, Bayer, Biosidus, Glaxo, Boehringer Ingelheim, Astra Zeneca, Merck.			
Miembro del Board de Speakers de AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi , Servier, Raffo , Baliarda.									
Investigadora en Estudio de Novonordisk , Abbie, Bayer, Biosidus, Glaxo, Boehringer Ingelheim, Astra Zeneca, Merck.									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
3	Royalties or licenses	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
4	Consulting fees	☒ None <table border="1"> <tr><td>none</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	none								
none											
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	☒ None <table border="1"> <tr><td>none</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	none								
none											
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td>none</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	none								
none											
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
ju m p j u m	Leadership or fiduciary role in other board, society, committee or	☒ None <table border="1"> <tr> <td>Asesora grupo Comité Nefrología de la Sociedad de diabetes y de la de Metabolismo y Diabetes de</td> <td></td> </tr> </table>	Asesora grupo Comité Nefrología de la Sociedad de diabetes y de la de Metabolismo y Diabetes de								
Asesora grupo Comité Nefrología de la Sociedad de diabetes y de la de Metabolismo y Diabetes de											

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
p1 0	advocacy group, paid or unpaid	la Sociedad de Nefrologia -Directora Curso de Obesidad y Diabetes de la Sociedad de Nefrología	
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
		none	
13	Other financial or non-financial interests	☒ None	
Please place an "X" next to the following statement to indicate your agreement: X ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form. X			

Albert

04-08-2026

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: Guillermo De'Marziani

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
ju m pj u m	Leadership or fiduciary role in other board, society, committee or	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
p1 0	advocacy group, paid or unpaid								
11	Stock or stock options	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.									



Guillermo De'Marziani

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: María J. Conforti

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; margin-top: 10px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
ju m pj u m	Leadership or fiduciary role in other board, society, committee or	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
p1 0	advocacy group, paid or unpaid		
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			



Conforti Maria Jimena

ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: Cecilia Araya

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None									
		<table border="1"> <tr> <td>Bagó</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Bagó								
Bagó											
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None									
		<table border="1"> <tr> <td>Novo Nordisk, Astra Zeneca, Boehringer Ingelheim, Bayer , Nolter(Adium), Bagó.</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Novo Nordisk, Astra Zeneca, Boehringer Ingelheim, Bayer , Nolter(Adium), Bagó.								
Novo Nordisk, Astra Zeneca, Boehringer Ingelheim, Bayer , Nolter(Adium), Bagó.											
6	Payment for expert testimony	☒ None									
		<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
7	Support for attending meetings and/or travel	☒ None									
		<table border="1"> <tr> <td>Novo Nordisk, Boehringer Ingelheim, Casasco, Baliarda, Elea, Siegfried, Bagó</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Novo Nordisk, Boehringer Ingelheim, Casasco, Baliarda, Elea, Siegfried, Bagó								
Novo Nordisk, Boehringer Ingelheim, Casasco, Baliarda, Elea, Siegfried, Bagó											
8	Patents planned, issued or pending	☒ None									
		<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None									
		<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>									
ju m pj u m	Leadership or fiduciary role in other board, society, committee or	☒ None									
		<table border="1"> <tr> <td>Sociedad Argentina de Diabetes</td> <td></td> </tr> </table>	Sociedad Argentina de Diabetes								
Sociedad Argentina de Diabetes											

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
p10	advocacy group, paid or unpaid		
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Dra Cecilia Araya



ICMJE DISCLOSURE FORM

Date: 03/08//2026
 Your Name: Carina Adjiman
 Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table> Click the tab key to add additional rows.						
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
3	Royalties or licenses	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
4	Consulting fees	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
ju m p j u m p 1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None 	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None 	
13	Other financial or non-financial interests	☒ None 	
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.			



ICMJE DISCLOSURE FORM

Date: 03/08//2026

Your Name: María F. Aranguren

Manuscript Title:

Brecha terapéutica en pacientes de muy alto riesgo con enfermedad cardiorrenal: análisis de la implementación de terapias basadas en la evidencia

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i4.21027>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table> Click the tab key to add additional rows.							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	☒ None <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ None	
		Abbott, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi, Lilly, Raffo, Adium, Elea, Bagó, Bernabó, Servier	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None	
		Abbott, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi, Lilly, Raffo, Adium, Elea, Bagó, Bernabó, Servier	
6	Payment for expert testimony	☒ None	
		Abbott, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi, Lilly, Raffo, Adium, Elea, Bagó, Bernabó, Servier	
7	Support for attending meetings and/or travel	☒ None	
		, Novo Nordisk, Boehringer Ingelheim, Sanofi, , Bagó, Servier	
8	Patents planned, issued or pending	☒ None	
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None	
		Abbott, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Sanofi, Lilly, Raffo, Adium, Elea, Bagó, Bernabó, Servier	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
ju m p j u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None	<table border="1"> <tr> <td>Sociedad Argentina de Diabetes</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>	Sociedad Argentina de Diabetes					
Sociedad Argentina de Diabetes									
11	Stock or stock options	☒ None	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
13	Other financial or non-financial interests	☒ None	<table border="1"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> </table>						
Please place an "X" next to the following statement to indicate your agreement: ☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.									


 FLORENCIA ARANGUREN
 CLINICA MEDICA - DIABETES
 M.N. 107999